Zogenix — Investor Presentation (September 2015)
22 slides from Zogenix's investor presentation, Sep 29, 2015
Slide 1: Company Overview
1 NASDAQ: Company Overview September 2015 Exhibit 99.1
Slide 2: Forward Looking Statements
2 Forward Looking Statements Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements. Words such as "believes," "plans," "expects," "will," "potential" and similar expressions are intended to identify forward-lo
Slide 3: Products for the Treatment of CNS Disorders
3 Developed, Commercialized and Monetized CHRONIC PAIN ACUTE MIGRAINES EPILEPSY (DRAVET SYNDROME) SCHIZOPHRENIA ONCE-MONTHLY ZX008 (low-dose fenfluramine) Late Stage Development Global Opportunities Products for the Treatment of CENTRAL NERVOUS SYSTEM (CNS) Disorders
Slide 4: The Zogenix Opportunity
4 The Zogenix Opportunity PROMISING PIPELINE of Differentiated CNS Compounds in Late-Stage Clinical Development FULLY FUNDED For Multiple Milestones Through 2017 for 2 Clinical Programs EXPERIENCED TEAM with Successful Track Record of Drug Development HIGHLY EFFICIENT Path to Commercialization and P
Slide 5: ZX008 Dravet Syndrome
5 ZX008 Dravet Syndrome Worldwide Rights Orphan Drug Designation in U.S. and E.U. Expect to Commercialize Directly in U.S. and E.U. Asia-Pacific Partnering Opportunity PHASE 3 START Q4 2015
Slide 6: Dravet Syndrome: A Catastrophic Illness
6 Dravet Syndrome: A Catastrophic Illness Intractable, Severe Epilepsy Which Begins In Infancy Estimated 16,000 - 29,000 Patients in the U.S. and E.U. Approximately 75 Specialty Treatment Centers in U.S. and similar in E.U. Does not Effectively Respond to Traditional Epilepsy Medications Cognitive,
Slide 7: First Published Study of Fenfluramine Efficacy in Dravet Syndrome
7 First Published Study of Fenfluramine Efficacy in Dravet Syndrome Long-term open-label study of fenfluramine as an adjunctive anticonvulsant therapy 12 Dravet syndrome patients, 11 with confirmatory genetic mutation 70% of patients seizure-free at last assessment Range of 1-19 years of seizure fre
Slide 8: Recent Multi-Year Follow-Up Analysis Further Supports Fenfluramine Efficacy in Dravet Syndrome
8 Recent Multi-Year Follow-Up Analysis Further Supports Fenfluramine Efficacy in Dravet Syndrome This analysis includes 10 patients from the original cohort (5 years of follow- up) and 2 patients who began treatment in 2011 (4 years of follow-up) Patients age range of 9 months to 13 years at treatme
Slide 9: Pre-Clinical Evidence of Fenfluramine Activity in an Established Model of Dravet Syndrome
9 Pre-Clinical Evidence of Fenfluramine Activity in an Established Model of Dravet Syndrome Wildtype scn1Lab Mutant Zhang, Yifen, et al. PLOS May 12, 2015. Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin
Slide 10: History of Therapeutic Use of Fenfluramine
10 History of Therapeutic Use of Fenfluramine Approved Use in Adult Obesity Approved Use in Adult Obesity Experimental Use in Pediatric Neurobehavioral Conditions Experimental Use in Pediatric Neurobehavioral Conditions Off-Label Combination Use with Phentermine in 1980s/1990s, Often At Higher than
Slide 11: Established Pathway to Phase 3 Development and Regulatory Submissions
11 Established Pathway to Phase 3 Development and Regulatory Submissions Summary of Correspondence with FDA and European Agencies Recognition That Benefit/Risk in Dravet Syndrome Is Different to Use of Fenfluramine as an Appetite Suppressant Confirmed Path to IND / CTA Submissions to Initiate Phase
Slide 12: ZX008 Summary of Phase 3 Study Design
12 ZX008 Summary of Phase 3 Study Design Placebo ZX008 High dose ZX008 Low dose 8 WEEKS BASELINE OBSERVATION 12 WEEKS TREATMENT Initial Screen Open Label Safety Study N = 105 Ages 2 – Two identical studies, one U.S. and one multinational (mainly Europe) Q4 2015 initiation of U.S. study Primary endpo
Slide 13: Market Research: ZX008 Could be Used as First or Second Adjunct Therapy in Dravet Syndrome
13 Market Research: ZX008 Could be Used as First or Second Adjunct Therapy in Dravet Syndrome E.U. 57% % of Neuros Who Would Use ZX008 as a 1 st or 2 nd Adjunct Therapy Source: BioStrategies Market Research, May 2015 U.S. 81% Neurologists… Were Overwhelmingly Positive Regarding the Safety and Effica
Slide 14: Established Product Protection
14 Established Product Protection ORPHAN DRUG STATUS May Provide 10 Years of Market Exclusivity in E.U. and 7 Years in U.S. When Obtained in Japan, ODS Will Provide 10 Years Exclusivity PATENTS PENDING (1) Use of Fenfluramine in Dravet Syndrome and Elements of a Future REMS Program Ongoing Preclinic
Slide 15: Schizophrenia
15 Schizophrenia Proprietary Subcutaneous Once-Monthly Antipsychotic Highly Differentiated Profile Worldwide Rights Co-Development/Commercialization Opportunity PHASE 3 READY Q1 2016
Slide 16: Market Overview of LAIs for Treatment of Schizophrenia
16 Market Overview of LAIs for Treatment of Schizophrenia LAIs for Schizophrenia LAIs for Schizophrenia 2.4 Million Diagnosed Patients in the U.S. Treatment Compliance Can Be Challenging Treatment Paradigm Evolving Towards Earlier Use of LAIs PATIENTS PHYSICIANS Large, Growing $4 – 5B WW Market High
Slide 17: RELDAY Has a Differentiated LAI Profile
17 RELDAY Has a Differentiated LAI Profile Designed to overcome complexities associated with other long acting injections – No oral supplementation / complicated loading dose regimens – Initiation dose identical to maintenance dose Once-monthly dosing interval Subcutaneous administration – Potential
Slide 18: Strong Physician Endorsement of Product Attributes Relative to Marketed LAIs
18 Strong Physician Endorsement of Product Attributes Relative to Marketed LAIs 69% 61% Highest on Clinical and Product Merits Very Positive/Positive On Initial Reaction Source: BioStrategies Group, 2013, N=150 U.S. Physicians, 173 E.U. Physicians U.S. E.U. RELDAY INVEGA® SUSTENNA® Risperdal® CONSTA
Slide 19: Development Progress to Date
19 Development Progress to Date A Proven, Effective and Safe Molecule for the Treatment of Schizophrenia Single-Dose Study Successfully Completed Multi-Dose Study Initiated: Top-Line Results Q3 2015 Issued and Pending Patents Through at Least 2034 Formulation Technology also Amenable to Three-Monthl
Slide 20: 2015 Focused on Execution in Late-Stage Development
20 2015 Focused on Execution in Late-Stage Development ZX008 2016 Q1 Q2 Q3 Q4 Submit IND / CTAs Initiate U.S. Phase 3 Initiate EU Phase 3 (Q1 2016) Targeting Phase 3 Results Prepare for NDA/MAA Submission End of Phase 2 FDA Meeting Initiate Phase 3 with Partner Phase 1B Results Expected AES scientif
Slide 21: Financial Highlights
21 Financial Highlights Cash ( balance at 6-30-15 plus follow-on offering net proceeds) $169.4 M Debt (1) (as of 6-30-15) $20.0 M Guidance for 2H-2015 R&D expenses G&A expenses $19 M – $22 M $14 M – $16 M Common Shares Outstanding (2) 24.6 million Fully Diluted Shares (3) 29.0 million (1) Excludes $
Slide 22: NASDAQ:
22 NASDAQ: PROMISING PIPELINE FULLY FUNDED CLINICAL PROGRAMS EXPERIENCED, SUCCESSFUL TEAM SIGNIFICANT NEAR-TERM MILESTONES HIGHLY EFFICIENT PATH TO COMMERCIALIZATION